Startseite

Aktien

Ascentage Pharma Group

Nachrichten

Ascentage Pharma Group Aktie

Aktie

ISIN: KYG0519B1023 WKN: A2PUCQ Land Flagge KY

Kaiman-Inseln

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

5,0500

EUR

+0,20 %

+0,0100 EUR

Letzter Kurs 22:23:58 Lang & Schwarz

Ascentage Pharma Group Aktie kaufen

Geldkurs

22:23:58

4,8000

EUR

3.030 STK

Briefkurs

22:23:58

5,3000

EUR

3.030 STK

Verkauf

Kauf

Hinweis
Verlängerte Handelszeiten
Mo-Fr von 07:30 bis 23:00 Uhr
Neu: Samstag von 14:00 bis 19:00 Uhr

Neueste Nachrichten

BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand \| DelveInsight 12.02.26 · PR Newswire (engl.) · Roche Holding
Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 09.02.26 · globenewswire · Ascentage Pharma Group
Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 06.02.26 · globenewswire · Ascentage Pharma Group
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference 15.01.26 · globenewswire · Ascentage Pharma Group
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 07.01.26 · globenewswire · Ascentage Pharma Group
Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference 17.12.25 · globenewswire · Ascentage Pharma Group
ASH 2025 \| Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60% 09.12.25 · globenewswire · Ascentage Pharma Group
ASH 2025 \| Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment 09.12.25 · globenewswire · Ascentage Pharma Group
ASH 2025 \| Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP 09.12.25 · globenewswire · Ascentage Pharma Group
Record Resources Announces $500,000 Brokered LIFE Offering to Advance Strategic Growth Initiatives in Gabon, Africa 08.12.25 · newsfile · REC Silicon
ASH 2025 \| Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances 08.12.25 · globenewswire · Ascentage Pharma Group
Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting 06.12.25 · globenewswire · Ascentage Pharma Group

1
2
3
…
4

BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology ... 136 Leser

BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology ... 136 Leser
Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 128 Leser
Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 128 Leser

Roche's Susvimo FDA Approval Marks New Era in Diabetic Macular Edema Treatment Market \| ... 556 Leser
Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and ... 372 Leser
ReconAfrica Announces C$10 Million Overnight Marketed Offering for the Advancement of Operational ... 308 Leser
Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia ... 248 Leser
Live from ASCO 2025 \| Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy ... 232 Leser
Record Resources Announces $500,000 Brokered LIFE Offering to Advance Strategic Growth Initiatives ... 204 Leser
ASH 2025 \| Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib ... 200 Leser
Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at ... 200 Leser
Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line ... 196 Leser
ASH 2025 \| Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of ... 192 Leser